دورية أكاديمية
A Novel Protozoa Parasite-Derived Protein Adjuvant Is Effective in Immunization with Cancer Cells to Activate the Cancer-Specific Protective Immunity and Inhibit the Cancer Growth in a Murine Model of Colorectal Cancer
العنوان: | A Novel Protozoa Parasite-Derived Protein Adjuvant Is Effective in Immunization with Cancer Cells to Activate the Cancer-Specific Protective Immunity and Inhibit the Cancer Growth in a Murine Model of Colorectal Cancer |
---|---|
المؤلفون: | Rajesh Mani, Chloe G. Martin, Kanal E. Balu, Qingding Wang, Piotr Rychahou, Tadahide Izumi, B. Mark Evers, Yasuhiro Suzuki |
المصدر: | Cells, Vol 13, Iss 2, p 111 (2024) |
بيانات النشر: | MDPI AG, 2024. |
سنة النشر: | 2024 |
المجموعة: | LCC:Cytology |
مصطلحات موضوعية: | Toxoplasma gondii, protein adjuvant, cancer immunotherapy, CD8+ T cells, cytotoxic activity, IFN-γ, Cytology, QH573-671 |
الوصف: | Cancer-specific CD8+ cytotoxic T cells play important roles in preventing cancer growth, and IFN-γ, in addition to IL-12 and type I interferon, is critical for activating CD8+ cytotoxic T cells. We recently identified the capability of the amino-terminus region of dense granule protein 6 (GRA6Nt) of Toxoplasma gondii, an intracellular protozoan parasite, to activate IFN-γ production of microglia, a tissue-resident macrophage population. Therefore, in the present study, we examined whether recombinant GRA6Nt protein (rGRA6Nt) functions as an effective adjuvant to potently activate cancer-specific protective immunity using a murine model of MC38 colorectal cancer (CRC). When mice were immunized with non-replicable (either treated with mitomycin C or irradiated by X-ray) MC38 CRC cells in combination with rGRA6Nt adjuvant and received a challenge implantation of replication-capable MC38 tumor cells, those mice markedly inhibited the growth of the implanted tumors in association with a two-fold increase in CD8+ T cell density within the tumors. In addition, CD8+ T cells of the immunized mice secreted significantly increased amounts of granzyme B, a key mediator of the cytotoxic activity of CD8+ T cells, and IFN-γ in response to MC38 CRC cells in vitro when compared to the T cells from unimmunized mice. Notably, the protective effects of the immunization were specific to MC38 CRC cells, as the immunized mice did not exhibit a significantly inhibited growth of EL4 lymphoma tumors. These results indicate that rGRA6Nt is a novel and effective protein adjuvant when used in immunizations with non-replicable cancer cells to potently activate the protective immunity specifically against the cancer cells employed in the immunization. |
نوع الوثيقة: | article |
وصف الملف: | electronic resource |
اللغة: | English |
تدمد: | 2073-4409 |
العلاقة: | https://www.mdpi.com/2073-4409/13/2/111Test; https://doaj.org/toc/2073-4409Test |
DOI: | 10.3390/cells13020111 |
الوصول الحر: | https://doaj.org/article/c042eed071fe47d4b0aacbacb46c76b1Test |
رقم الانضمام: | edsdoj.042eed071fe47d4b0aacbacb46c76b1 |
قاعدة البيانات: | Directory of Open Access Journals |
كن أول من يترك تعليقا!